Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump

Plus news about United Therapeutics, Liquidia, Sanofi, Pharming, Skyhook Bio and Altay Therapeutics. Ultragenyx Pharmaceutical sells second PRV this month: The commercial-stage rare disease drugmaker sold its second priority review voucher for

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Finance & Markets

Bank Stocks Brace for Higher Rates

RBC Capital Markets Large Cap US Bank Analyst Gerard Cassidy joins Bloomberg Open Interest to explain why Bank of America’s regulatory settlement wasn’t a complete surprise and how rising rates could…

More from Wednesday 14 October →